The ARHGAP32 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population enabling targeted disruption of ARHGAP32. This polyclonal pool contains a heterogeneous collection of cells with diverse loss-of-function alleles, providing a robust model for studying ARHGAP32 function without clonal selection artifacts. The polyclonal format mitigates off-target effects and preserves biological variability, suitable for high-throughput screening and pooled assays.
The HeLa host cell line is an immortalized human cervical adenocarcinoma epithelial cell line widely employed across biomedical research. Derived from cervical cancer tissue, HeLa cells exhibit robust growth characteristics and have been instrumental in numerous discoveries in cell biology, signal transduction, and cancer research. Their epithelial origin and well-characterized genomic landscape make them a versatile platform for gene perturbation studies, particularly in pathways relevant to tumor cell migration, proliferation, and cytoskeletal organization.
ARHGAP32 encodes a Rho GTPase-activating protein that inactivates the small GTPases Cdc42 and Rac1 through its GAP domain, thereby suppressing downstream actin polymerization and regulating cell morphology. It functions as a critical node coupling membrane receptor activity to cytoskeletal remodeling. ARHGAP32 is activated by NMDA receptor stimulation, BDNF, and GABA receptor signaling, and interacts with synaptic scaffold proteins GluN1, GluN2B, PSD-95, and DLG4, as well as GABARAP. Upon activation, ARHGAP32 downregulates Cdc42 and Rac1, which in turn modulates effectors such as PAK, LIMK, and cofilin, ultimately controlling actin filament dynamics.
In HeLa cells, ARHGAP32 disruption is relevant for investigating tumor cell motility and invasion. ARHGAP32 is implicated in glioma and breast cancer, where its loss promotes a migratory phenotype via dysregulated actin dynamics. The polyclonal knockout HeLa pool allows dissection of oncogenic signaling in a cancer-relevant epithelial background. Although ARHGAP32 links NMDA receptor activity to cytoskeletal changes, the primary utility remains in oncology and cytoskeletal biology due to the non-neuronal nature of HeLa cells.
This product is suited for advanced applications including Rho GTPase signaling in cancer, synaptic plasticity studies, neuronal development, and drug target validation. Representative assays include western blotting, GTPase activity pull-downs, immunofluorescence for actin, transwell migration assay, co-immunoprecipitation, and RNA-seq. For more information or to discuss custom applications, contact Ascent Research.
